Janux Therapeutics Inc. (JANX)
Janux Therapeutics Inc. (JANX) Stock Price, Analysis & Data
| Bid | 11.53 |
| Market Cap | 1.02B |
| Revenue (ttm) | 24M |
| Net Income (ttm) | -102.59M |
| Beta | 2.51 |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | n/a |
| Forward PE | -6.24 |
| P/B (ttm) | 1.06 |
| P/S (ttm) | 42.59 |
| Earnings Date | Nov 5, 2026 |
| Ask | 20.54 |
| Volume | 389,598 |
| Avg. Volume (20D) | 1,041,898 |
| Open | 16.44 |
| Previous Close | 16.52 |
| Day's Range | 16.33 - 16.82 |
| 52-Week Range | 12.12 - 35.34 |
| Analyst | Strong Buy |
| Price Target | 32 (91.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment...
Financial Performance
In 2025, Janux Therapeutics's revenue was 10M, a decrease of -5.55% compared to the previous year's 10.59M. Earnings were -113.63M, an increase of 64.69%.
Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for JANX stock is "Strong Buy". The 12-month stock price forecast is 32, which is upside of 91.39% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
